• No results found

Clinical pharmacology of cannabinoids in early phase drug development Zuurman, H.H.

N/A
N/A
Protected

Academic year: 2021

Share "Clinical pharmacology of cannabinoids in early phase drug development Zuurman, H.H."

Copied!
2
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

Clinical pharmacology of cannabinoids in early phase drug development

Zuurman, H.H.

Citation

Zuurman, H. H. (2008, May 28). Clinical pharmacology of cannabinoids in early phase drug development. Retrieved from

https://hdl.handle.net/1887/12869

Version: Corrected Publisher’s Version License:

Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden

Downloaded from: https://hdl.handle.net/1887/12869

Note: To cite this publication please use the final published version (if

applicable).

(2)

 DMJOJDBMQIBSNBDPMPHZPGDBOOBCJOPJETJOFBSMZQIBTFESVHEFWFMPQNFOU

DVSSJDVMVNWJUBF

-JOFLF;VVSNBOXBTCPSOJO)PPHF[BOE4BQQFNFFS 5IF/FUIFSMBOET PO

+BOVBSZ    4IF EJE OPU PCUBJO IFS "UIFOFVN EJQMPNB WXP BU UIF

8FTTFM(BOTGPSU$PMMFHFJO(SPOJOHFO#FGPSFHPJOHUPVOJWFSTJUZTIFXPS

LFEBDPVQMFPGZFBSTGPSBUFNQPSBSZFNQMPZNFOUBHFODZBOEBTBWPMVOUFFS

JOBESVHSFIBCJMJUBUJPODFOUSF*OTIFQBTTFEB$PMMPRVJVN%PDUVN

1IZTJPUIFSBQZ BOE JO  UIF GPVOEBUJPO DPVSTF 1IZTJPUIFSBQZ BOE UIF

$PMMPRVJVN%PDUVN.FEJDBM4DJFODF*OTIFDPNQMFUFEUIFEPDUPSBM

QIBTFPG.FEJDBM#JPMPHZBUUIF'SFF6OJWFSTJUZPG"NTUFSEBN)FSNBKPS

DPVSTFXBT/FVSPQIBSNBDPMPHZ4VCTFRVFOUMZTIFTUVEJFE.FEJDJOFBOE

HPUIFS.FEJDBMEFHSFFJO*O0DUPCFSTIFTUBSUFEXPSLJOHBUUIF

$FOUSFGPS)VNBO%SVH3FTFBSDI DIESJO-FJEFOBT$MJOJDBM4DJFOUJTU DFP

1SPG%S"'$PIFO5IFSFTFBSDIEFTDSJCFEJOUIJTUIFTJTXBTQFSGPSNFE

BU DIES *O +VOF  TIF XBT SFHJTUFSFE BT B $MJOJDBM 1IBSNBDPMPHJTU

$VSSFOUMZTIFXPSLTBT$MJOJDBM"TTFTTPSBUUIF%VUDI.FEJDJOFT&WBMVBUJPO

#PBSE'SPN+VMZPOXBSETTIFXJMMXPSLGPS)PGGNBOO-B3PDIF #BTFM  4XJU[FSMBOE

Referenties

GERELATEERDE DOCUMENTEN

Peripheral blood cells were stained with HLA-A2.1 tetramers containing the tyrosinase368–376 peptide followed by staining with a panel of lineage antibodies, as described in

Blades and blade fragments seem to have been especially used for longitudinal motions, mainly on plant material (7/12). Flake and flake fragments are used in different motions on

This shape also occurs in the combination artefacts (see below). The shape is the result of intensive use in a repetitive abrasive motion, carried out from different angles. In

QIBSNBDPLJOFUJDT " OPOMJOFBS EPTF EFQFOEFOU JODSFBTF JO QMBTNB BWF DPODFOUSBUJPOT XBT PCTFSWFE XJUI NPEFSBUF UP IJHI JOUFSTVCKFDU WBSJBCJMJUZ XJUI IJHIFS

TVCKFDUT 5XFOUZPOFNBMFIFBMUIZWPMVOUFFSTXFSFTDSFFOFEBOEGPVOEUPCFIFBMUIZ EFUFSNJOFE GSPN NFEJDBM IJTUPSZ QIZTJDBM FYBNJOBUJPO MBCPSBUPSZ BOE VSJOF TDSFFOT BOE FMFDUSPDBSEJPHSBQIZ

TVCKFDUT0OMZUIFTMPXJOGVTJPOPG0SHQSPEVDFEQTZDIPMPHJDBMBE WFSTFFGGFDUT TPUIJTXBTVOSFMBUFEUPBSBQJEJODSFBTFJOQMBTNB PSCSBJO

UJWFNFBTVSFPGTFEBUJPOGPSCFO[PEJB[FQJOFT 5IFTFUXPDPNQPVOET BSFUIFSFGPSFOPUTVJUBCMFGPSQSPWJEJOHTFEBUJPOGPSEBZDBSFTVSHJDBMQSP DFEVSFT " XFMMLOPXO DIBSBDUFSJTUJD PG NJEB[PMBN

5 For the development of cannabinoids in general it is worthwhile to unravel the complex cardiovascular mechanisms in humans since cardiovascular side effects